Compare LZM & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZM | BCYC |
|---|---|---|
| Founded | 2021 | 2009 |
| Country | Isle of Man | United Kingdom |
| Employees | 142 | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.4M | 456.4M |
| IPO Year | N/A | 2019 |
| Metric | LZM | BCYC |
|---|---|---|
| Price | $4.08 | $5.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $7.00 | ★ $17.56 |
| AVG Volume (30 Days) | 193.6K | ★ 309.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $510.94 | N/A |
| Revenue Next Year | $217.65 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.90 | $5.03 |
| 52 Week High | $6.23 | $10.84 |
| Indicator | LZM | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 37.70 | 39.78 |
| Support Level | $3.71 | $5.03 |
| Resistance Level | $4.42 | $5.90 |
| Average True Range (ATR) | 0.25 | 0.28 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 8.00 | 23.53 |
Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining and to become an emerging supplier of responsibly sourced, lower-carbon and lower-sulfur dioxide emission metals to the battery, EV, and hydrogen markets modern pre-development exploration-stage metals company. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.